Literature DB >> 12592348

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.

C Schoch, T Haferlach, W Kern, S Schnittger, U Berger, R Hehlmann, W Hiddemann, A Hochhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12592348     DOI： 10.1038/sj.leu.2402813

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections.

Authors:  Victoria Bedell; Stephen J Forman; Karl Gaal; Vinod Pullarkat; Lawrence M Weiss; Marilyn L Slovak
Journal:  J Mol Diagn       Date:  2007-11       Impact factor: 5.568

2.  Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.

Authors:  Ismael Soltani; Hanen Gharbi; Islem Ben Hassine; Ghada Bouguerra; Kais Douzi; Mouheb Teber; Salem Abbes; Samia Menif
Journal:  Funct Integr Genomics       Date:  2016-09-16       Impact factor: 3.410

3.  A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.

Authors:  Masayoshi Masuko; Tatsuo Furukawa; Takashi Abe; Reiko Wada; Soichi Maruyama; Toshiki Kitajima; Yasuhiko Shibasaki; Ken Toba; Masahiko Okada; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2009-06-30       Impact factor: 2.490

4.  Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Authors:  Sureyya Bozkurt; Burak Uz; Yahya Buyukasik; Ozlen Bektas; Ayten Inanc; Hakan Goker; Emin Kansu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 5.  Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-07-26

6.  Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Authors:  Theo D Kim; Seval Türkmen; Michaela Schwarz; Gökben Koca; Hendrik Nogai; Christiane Bommer; Bernd Dörken; Peter Daniel; Philipp le Coutre
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

7.  Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Authors:  Simona Soverini; Gianantonio Rosti; Ilaria Iacobucci; Michele Baccarani; Giovanni Martinelli
Journal:  Oncologist       Date:  2011-05-31

8.  Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.

Authors:  Wiltrud Haaß; Helga Kleiner; Christel Weiß; Claudia Haferlach; Brigitte Schlegelberger; Martin C Müller; Rüdiger Hehlmann; Wolf-Karsten Hofmann; Alice Fabarius; Wolfgang Seifarth
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

Review 9.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

10.  A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Moneeb Abdullah Kassem Othman
Journal:  Mol Cytogenet       Date:  2012-08-20       Impact factor: 2.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.